Results 21 to 30 of about 14,917 (246)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension [PDF]

Life
Esaxerenone, which blocks aldosterone binding, is approved to treat hypertension but not heart failure. We aimed to understand esaxerenone’s efficacy in treating chronic heart failure.
Akira Sezai, Msasnori Abe, Takashi Maruyama, Makoto Taoka, Hisakuni Sekino, Masashi Tanaka   +5 more
doaj   +2 more sources

Eplerenone [PDF]

Nature Reviews Drug Discovery, 2003
Data from animal studies and clinical trials indicate that aldosterone causes cardiovascular and renal injury through mineralocorticoid receptor–dependent mechanisms. However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific ...
Ruth, Brown, Jeremy, Quirk, Peter, Kirkpatrick   +2 more
openaire   +4 more sources

Eplerenone improves kidney function and cardiac performance in obese male mice. [PDF]

Diabet Med
Abstract Aims Renin‐angiotensin‐aldosterone system (RAAS) activation mediates obesity‐associated cardiorenal dysfunction. Due to an incomplete understanding of the molecular mechanisms, the clinical use of RAAS antagonism in obesity‐associated cardiometabolic complications remains uncertain.
Banah AK, Qi B, Koh R, Lawlor A, Wang T, Musale V, Mains J, Murdoch CE, Kang L.   +8 more
europepmc   +2 more sources

A Prospective Study of Eplerenone in the Treatment of Patients with Glomerulonephritis

Biomedicines, 2023
Background: High aldosterone levels contribute to kidney disease progression, while spironolactone in combination with ACEi or ARBs can potentially reduce proteinuria and ameliorate kidney function deterioration.
Marios Papasotiriou, Georgia Andrianna Georgopoulou, Adamantia Mpratsiakou, Theodoros Ntrinias, Georgios Lyras, Dimitrios S. Goumenos, Evangelos Papachristou   +6 more
doaj   +1 more source

Real-world practice patterns of eplerenone use for central serous chorioretinopathy

International Journal of Retina and Vitreous, 2023
Purpose To report eplerenone use by retina specialists worldwide for central serous chorioretinopathy (CSCR). Methods A self-reporting questionnaire was distributed to retina specialists worldwide to gather clinicians’ perspectives on CSCR cases treated,
Ramesh Venkatesh, Vishma Prabhu, Aishwarya Joshi, Rubble Mangla, Rishi Singh, Lihteh Wu, Paolo Lanzetta, Baruch Kuppermann, Francesco Bandello, Francine Behar Cohen, Jay Chhablani   +10 more
doaj   +1 more source

Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case evaluating PDT and eplerenone therapy in a patient with bilateral bullous central serous chorioretinopathy. Observations: A 30-year-old male was referred for worsening bilateral bullous central serous chorioretinopathy (bCSCR ...
William J. Anderson, Bradley T. Smith
doaj   +1 more source

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy

Scientific Reports, 2022
To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (
Lisa Toto, Rossella D’Aloisio, Chiara De Nicola, Federica Evangelista, Maria Ludovica Ruggeri, Luca Cerino, Maria Beatrice Simonelli, Agbéanda Aharrh-Gnama, Marta Di Nicola, Annamaria Porreca, Rodolfo Mastropasqua   +10 more
doaj   +1 more source

Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats [PDF]

Diabetes & Metabolism Journal, 2012
BackgroundAldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of the renin-angiotensin-aldosterone system.
Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim   +14 more
doaj   +1 more source

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)

Лечащий Врач, 2023
The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova, R. I. Stryuk, V. V. Evdokimov, A. K. Kaptaeva   +3 more
doaj   +1 more source

Clinical Determinants and Prognostic Implications of Renin and Aldosterone in Patients with Symptomatic Heart Failure [PDF]

, 2020
Aims Activation of the renin-angiotensin-aldosterone system plays an important role in the pathophysiology of heart failure (HF) and has been associated with poor prognosis.
Anker, Stefan D., Dickstein, Kenneth, Duarte, Kevin, Ferreira, Joao Pedro, Girerd, Nicolas, Kobayashi, Masatake, Lamiral, Zohra, Lang, Chim C., Metra, Macro, Ng, Leong L., Preud'homme, Gregoire, Rossignol, Patrick, Samani, Nilesh J., Stienen, Susan, ter Maaten, Jozine M., van Veldhuisen, Dirk J., Voors, Adriaan A., Zannad, Faiez   +17 more
core   +5 more sources